<SEC-DOCUMENT>0001558370-24-000426.txt : 20240123
<SEC-HEADER>0001558370-24-000426.hdr.sgml : 20240123
<ACCEPTANCE-DATETIME>20240123090426
ACCESSION NUMBER:		0001558370-24-000426
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240123
FILED AS OF DATE:		20240123
DATE AS OF CHANGE:		20240123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		24550585

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20240123x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 1/23/2024 01:57:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF JANUARY 2024</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Carl Jacobsens Vej 30</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2500 Valby</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background:#ffffff;">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background:#ffffff;">&#160;in Genmab A/S&#8217;s registration statements on&#160;</font><font style="background:#ffffff;">Form&#160;S-8</font><font style="background:#ffffff;">&#160;(File&#160;No. 333-232693, </font>333-232693 and 333-262970<font style="background:#ffffff;">)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">nthony</p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: JANUARY 23, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.1127167%;width:102.22%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">O</font></p></div></div></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</u></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.55%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:86.44%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Company Announcement Dated January 23, 2024: Genmab Announces Net Sales of DARZALEX&#174; (daratumumab) for 2023</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20240123xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 1/23/2024 01:57:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="tmb-20240123xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45pt;width:151.5pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab Announces Net Sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9.75pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;"> (daratumumab) for 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Company Announcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Net sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> in 2023 totaled USD 9,744 million</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">COPENHAGEN, Denmark; January 23, 2024 &#8211; </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Genmab A/S</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> in the U.S.), as reported by Johnson &amp; Johnson were USD 9,744 million in 2023.</b><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;"> Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.   </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Genmab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab&#8217;s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO&#8482;) antibody medicines.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab</font><font style="font-family:'Arial','Helvetica','sans-serif';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Contact:</b></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Marisol Peron, Senior Vice President, Global Communications &amp; Corporate Affairs</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +1 609 524 0065; E: mmp@genmab.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Andrew Carlsen, Vice President, Head of Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +45 3377 9558; E: acn@genmab.com </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">This Company Announcement contains forward looking statements. The words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on www.genmab.com</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and the risk factors included in Genmab&#8217;s most recent Annual Report on Form 20-F and other filings </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HuMax</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; HexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; DuoHexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">, HexElect</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174; </sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and KYSO&#8482;. DARZALEX</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and DARZALEX FASPRO</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> are trademarks of Johnson &amp; Johnson.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 03</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Carl Jacobsens Vej 30</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/1</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">2500 Valby, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20240123xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20240123xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ ,H# 2(  A$! Q$!_\0
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MU]*=_:L:M-TG9]>VIU87%PQ<'*":L[--6:)**2EK,[@HHHH ***2@!:*2EH
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M[GA'[.'[2UW\6]6UCPOXFT==!\7Z4K/-!'N"2*K!'^5OF1E8@%23U!!ZX?\
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#I__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
